Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Calithera Biosciences Inc (EM) CALA

Healthcare Biotechnology
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Current News (EXPM:CALA)

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

GlobeNewswire June 29, 2023

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

GlobeNewswire May 19, 2023

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

GlobeNewswire January 9, 2023

Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update

GlobeNewswire November 14, 2022

Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

GlobeNewswire November 8, 2022

Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer

GlobeNewswire October 3, 2022

Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

GlobeNewswire August 15, 2022

Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

GlobeNewswire August 8, 2022
View More News ››

Opinion & Analysis (EXPM:CALA)

2018 Biotech Watchlist: 'no one space is going to dominate'

Streetwise Reports January 11, 2018
View More Opinion ››

Bullboard Posts (EXPM:CALA)

Calithera Biosciences, Inc. (CALA): Navigating the Challenge

http://beyondspx.com/2024/08/01/calithera-biosciences-inc-cala-navigating-the-challenges-of-precision-oncology/
MikeTester - August 2, 2024

What do you Know

Anybody know about this company? Has had a nice run in the last 3 mns
billybob22 - January 13, 2017
View more Bullboard ››

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp. operates as a waste to fuels company, focuses on wood waste byproducts conversion to renewable ...
View More »

Podcasts